Feb 5, 2026Metformin for Longevity: TAME Trial, Off-Label Use in Non-Diabetics, Safety, and ContraindicationsMetformin activates AMPK and has extensive epidemiological longevity data from diabetic populations. The TAME trial will provide the first RCT data for longevity in non-diabetics. Off-label use has meaningful risks including vitamin B12 depletion, GI effects, and contraindications.